Groupe Francais De Pneumo-Cancerologie — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Groupe Francais De Pneumo-Cancerologie appears in 25 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials25

Recruiting shown5

Roles2

SourceClinicalTrials.gov

Clinical trials

25 shown

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibNCT06620835 · lead sponsor · 2025-06-19

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 InsertionNCT06247826 · lead sponsor · 2024-01-15

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLCNCT05122806 · lead sponsor · 2021-09-22

Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)NCT05308966 · lead sponsor · 2022-05-03

Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)NCT05049044 · lead sponsor · 2020-12-18

ACTIVE_NOT_RECRUITING

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)NCT03305133 · lead sponsor · 2017-09-26

Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.NCT02785562 · lead sponsor · 2016-07-21

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)NCT02293733 · lead sponsor · 2014-01-01

Feasibility of re Biopsies at ProgressionNCT02086071 · lead sponsor · 2012-05-01

Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung CancerNCT01956331 · lead sponsor · 2009-03-01

Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)NCT00419042 · lead sponsor · 2006-07-01

Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)NCT00418704 · lead sponsor · 2006-05-01

Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)NCT00418743 · lead sponsor · 2005-12-01

Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLCNCT06552234 · collaborator · 2024-10-01

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumNCT06393816 · collaborator · 2024-06-13

RW Effectiveness of Lurbinectedin in Extensive Stage SCLCNCT05285033 · collaborator · 2022-04-01

PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %NCT04547504 · collaborator · 2020-12-22

ACTIVE_NOT_RECRUITING

Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung CancerNCT03801304 · collaborator · 2019-01-24

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFRNCT02178397 · collaborator · 2014-06-01

Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain MetastasesNCT02162537 · collaborator · 2013-12-01

Strategies for Maintenance Therapies in Advanced Non Small Cell Lung CancerNCT01631136 · collaborator · 2012-07-01

Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung CancerNCT00433563 · collaborator · 2008-04-01

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung CancerNCT00284778 · collaborator · 2006-02-01

Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung CancerNCT00199758 · collaborator · 2003-09-01

Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCGNCT00037713 · collaborator · 1998-09-01

Drugs studied in this sponsor's trials

13 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Groupe Francais De Pneumo-Cancerologie as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

cisplatin3

gemcitabine3

pemetrexed2

atezolizumab1

bevacizumab1

docetaxel1

erlotinib1

lurbinectedin1

cisplatin RxCUI 2555 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials gemcitabine RxCUI 12574 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 3 trials pemetrexed RxCUI 68446 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials atezolizumab RxCUI 1792776 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial bevacizumab RxCUI 253337 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial erlotinib RxCUI 337525 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lurbinectedin RxCUI 2374729 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial paclitaxel RxCUI 56946 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial pembrolizumab RxCUI 1547545 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial repotrectinib RxCUI 2670644 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial Tarceva RxCUI 337526 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial vinorelbine RxCUI 39541 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor13

collaborator12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.